Garcia-Prats AJ, et al. - In children treated for multidrug-resistant tuberculosis (MDR-TB), researchers described the pharmacokinetics, safety, and optimal dose of linezolid, an oxazolidinone antibiotic that binds to the 50S ribosomal subunit inhibiting protein synthesis. Participants in the study were 48 children, with 31 receiving a single dose of linezolid, and 17 receiving multiple doses. Findings revealed that the adverse effects associated with linezolid were frequent and sometimes severe, so careful monitoring of linezolid safety is needed. Low hemoglobin was the most common. Lower doses may approximate current adult target exposures compared to the doses currently used for MDR-TB treatment in children in many settings and may result in fewer adverse events.